Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Stratification by MYC expression has prognostic impact in MYC translocated B-cell lymphoma—Identifies a subgroup of patients with poor outcome

Research output: Contribution to journalJournal articleResearchpeer-review


  1. Unexpected, isolated activated partial thromboplastin time prolongation: A practical mini-review

    Research output: Contribution to journalReviewResearchpeer-review

  2. Heterozygous loss of Srp72 in mice is not associated with major hematological phenotypes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Addressing the room for improvement in management of acute promyelocytic leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Objective: In patients with large B-cell lymphoma (LBCL) according to WHO, the prognostic significance of MYC translocation is still not sufficiently clarified. We therefore aimed to investigate whether prognostication could be improved in patients with MYC translocation positive LBCL by additional stratification according to MYC and BCL2 protein expression levels or MYC translocation partner gene as well as concurrent BCL2 and/or BCL6 translocation (DH). Methods: From an unselected consecutive cohort of >600 patients with LBCL investigated with fluorescent in situ hybridization (FISH), 64 patients were diagnosed with MYC translocation positive LBCL and included in the study. They were further investigated for supplemental translocations with FISH and MYC and BCL2 protein expression with immunohistochemistry (IHC). Results: MYC expression >75% was associated with both reduced progression-free survival (PFS) and overall survival (OS) (PFS: HR 6.8 (95% CI 1.5-31), P = 0.004. OS: HR 4.3 (95% CI 0.9-21), P = 0.05). Immunoglobulin (IG) MYC translocation partner gene was related to high MYC protein expression (P = 0.047) but was not prognostic for PFS (P = 0.8) or OS (P = 0.6). DH did not confer a worse outcome compared to MYC single hit (SH). These findings were confirmed in a comparable, independent validation cohort of 28 patients with MYC translocation positive LBCL. All patients included in the survival analyses were treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) or R-CHOEP (R-CHOP + etoposide). Conclusion: These findings suggest that in patients with LBCL stratification by MYC protein expression level significantly improves the prognostic impact associated with MYC translocation.

Original languageEnglish
JournalEuropean Journal of Haematology
Issue number5
Pages (from-to)395-406
Number of pages12
Publication statusPublished - 2019

Bibliographical note

© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

    Research areas

  • B-cell, BCL2, MYC, WHO, fluorescent in situ hybridization, immunohistochemistry, lymphoma, prognostic, Immunohistochemistry, Translocation, Genetic, Lymphoma, B-Cell/diagnosis, Prognosis, Humans, Gene Expression Regulation, Neoplastic, Kaplan-Meier Estimate, Male, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Biomarkers, Tumor, Female, Proto-Oncogene Proteins c-myc/genetics, Neoplasm Staging, Oncogene Proteins, Fusion/genetics

ID: 56690324